口服泼尼松龙对非哮喘成人急性下呼吸道感染症状持续时间及严重程度的影响:一项随机临床试验
这项多中心、安慰剂对照随机试验在英格兰54家家庭诊所纳入401名无哮喘的急性咳嗽伴至少1项下呼吸道症状成人,口服泼尼松龙20 mg每日一次共5天未缩短咳嗽持续时间,也未显著降低症状严重程度,作者结论认为不应使用。
要点
- 泼尼松龙组与安慰剂组中位咳嗽持续时间均为5天,校正风险比1.11(95%CI 0.89-1.39;P=.36)。
- 第2至4天平均症状严重程度泼尼松龙组1.99分 vs 安慰剂组2.16分,校正差值-0.20(95%CI -0.40至0.00;P=.05)。
- 作者结论认为无哮喘成人急性下呼吸道感染不应使用口服糖皮质激素。
核心结论
- 作者结论认为,无哮喘成人急性下呼吸道感染不应使用口服糖皮质激素,因其不缩短症状持续时间也不降低症状严重程度。
研究设计与样本
- 多中心、安慰剂对照随机试验,2013年7月至2014年10月最终随访,在英格兰54家家庭诊所纳入401名无哮喘成人。
- 纳入标准为急性咳嗽伴至少1项下呼吸道症状、不需要立即抗生素治疗、无慢性肺病史且过去5年未使用哮喘药物。
- 干预为泼尼松龙20 mg片剂2片(n=199)或匹配安慰剂(n=202),每日一次共5天。
主要发现
- 401名随机化患者中,2名随机后立即退出,发现1名重复患者;398名有基线数据者平均年龄47岁(SD 16.0),63%女性,17%吸烟者,77%有痰,70%气短,47%喘息,46%胸痛,42%峰流速异常。
- 334名(84%)提供咳嗽持续时间数据,369名(93%)提供症状严重程度数据。
- 泼尼松龙组中位咳嗽持续时间5天(IQR 3-8天) vs 安慰剂组5天(IQR 3-10天),校正风险比1.11(95%CI 0.89-1.39;P=.36,α=.05)。
- 第2至4天平均症状严重程度泼尼松龙组1.99分 vs 安慰剂组2.16分,校正差值-0.20(95%CI -0.40至0.00;P=.05,α=.001)。
- 其他急性下呼吸道感染症状的持续时间和严重程度、峰流速异常持续时间、抗生素使用及非严重不良事件均未见显著治疗效应;无严重不良事件。
关键数值与推荐
- 主要结局咳嗽持续时间的最小临床重要差异为3.79天。
- 主要结局症状严重程度评分0分(未受影响)至6分(最严重),最小临床重要差异为1.66单位。
临床怎么用
- 作者结论认为无哮喘成人急性下呼吸道感染不应使用口服糖皮质激素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. OBJECTIVE: To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years. INTERVENTIONS: Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days. MAIN OUTCOMES AND MEASURES: The primary outcomes were duration of moderately bad or worse cough (0 to 28 days; minimal clinically important difference, 3.79 days) and mean severity of symptoms on days 2 to 4 (scored from 0 [not affected] to 6 [as bad as it could be]; minimal clinically important difference, 1.66 units). Secondary outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, and adverse events. RESULTS: Among 401 randomized patients, 2 withdrew immediately after randomization, and 1 duplicate patient was identified. Among the 398 patients with baseline data (mean age, 47 [SD, 16.0] years; 63% women; 17% smokers; 77% phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (84%) provided cough duration and 369 (93%) symptom severity data. Median cough duration was 5 days (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the placebo group (adjusted hazard ratio, 1.11; 95% CI, 0.89-1.39; P = .36 at an α = .05). Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40 to 0.00; P = .05 at an α = .001). No significant treatment effects were observed for duration or severity of other acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, or nonserious adverse events. There were no serious adverse events. CONCLUSIONS AND RELEVANCE: Oral corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults without asthma because they do not reduce symptom duration or severity. TRIAL REGISTRATION: ISRCTN.com Identifier: ISRCTN57309858.
引用
- Hay AD, Little P, Harnden A, et al. Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial. JAMA. 2017. PMID: 28829884. doi:10.1001/jama.2017.10572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。